Identification of clinically significant prostate cancer by prostate-specific antigen screening.


BACKGROUND The importance of screening for early-stage prostate cancer has been debated in the literature. However, there are well-established prognostic factors (Gleason score [GS], pretreatment prostate-specific antigen [PSA], and percent positive biopsy findings [%+Bx]) that predict biologically aggressive disease. These factors, together with a patient… (More)


  • Presentations referencing similar topics